Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087

HIV Clinical Trials

Volumn 8, Issue 1, 2007, Pages 45-52

  Evans, Scott R ^a   Fichtenbaum, Carl J ^b   Aberg, Judith A ^c,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Coronary heart disease; Friedewald equation; Hypertriglyceridemia; Low density lipoproteins

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DYSLIPIDEMIA; FRIEDEWALD EQUATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULTRACENTRIFUGATION;

ANTILIPEMIC AGENTS; CLINICAL TRIALS; HIV; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; PROCETOFEN; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 34047219900     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0801-45     Document Type: Article

References (29)

1. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
2. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
3. Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
5. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
6. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. HIV Med. 2005;6:114-121.
7. Assmann G, Schulte H. Triglycerides and atherosclerosis; results from the Prospective Cardiovascular Munster Study. Arterioscler Rev. 1991;22:51-57.
8. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-949.
10. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 2001;87:2B-7B.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):449-502.
12. Aberg JA, Zackin RA, Brobst SW, et al., for the ACTG 5087 team. A prospective, multicenter randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. AIDS Res Hum Retroviruses. 2005;21:757-767.
13. Lin L, Hedayat AS, Sinha BK, Yang M. Statistical methods in assessing agreement: models, issues, and tools. J Am Stat Assoc. 2002;97(457):257-270.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
15. Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-C-cholesterol. Clin Chem. 2002;48:489-498.
16. Nauck M, Rifai N. Analytical performance and clinical efficacy of three routine procedures for LDL-C cholesterol measurement compared with the ultracentrifugation-dextran sulfate-Mg(2+) method. Clin Chim Acta. 2000;294:77-92.
17. Pisani T, Gebski CP, Leary ET, Warnick GR, Ollington JF. Accurate direct determination of low-density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay. Arch Pathol Lab Med. 1995;119:1127-1135.
18. Cobbaert C, Broodman I, Swart GR, Hoogerbrugge N. Performance of a direct, immunoseparation based LDL-C-cholesterol method compared to Friedewald calculation and a polyvinyl sulphate precipitation method. Eur J Clin Chem Clin Biochem. 1995;33:417-424.
19. Gerber JG, Kitch DW, Aberg JA, et al. The safety and efficacy of fish oil in combination with fenofibrate (FF) in subjects on ART with hypertriglyceridemia (HTG) who had an incomplete response to either agent alone: results of ACTG A5186. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO. Oral presentation 146.
20. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation of and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
21. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276:37514-37519.
22. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42:81-92.
23. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(suppl 1):S141-148.
24. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-1211.
25. Tungsiripat M, Aberg JA. Dyslipidemia in HIV-infected individuals. Invited review. Cleveland Clinic J Med. 2005;72:1113-1120.
26. Aberg JA, Rosenkranz S, Fichtenbaum CJ, Alston B, Brobst SW, Segal Y, Gerber JG. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20:725-729.
27. Gerber JG, Rosenkranz S, Fichtenbaum CJ, et al. The effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of ACTG 5108 Study. JAIDS. 2005;39:307-312.
28. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-3450.
29. Carr R, Andre A, Bertz R. Concomitant administration of ABT-378/ritonavir (ABT-378/r). Results in a clinically important pharmacokinetic (PK) interaction with atorvastatin but not pravastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000. Abstract 1644.